35607-66-0
35607-66-0
Chemical Structure
Cefoxitin
- CAS No.: 35607-66-0
- Formula:C16H17N3O7S2
- Molecular Weight:427.45
IUPAC Name: (6R,7S)-3-((carbamoyloxy)methyl)-7-methoxy-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChIKey: WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
SMILES: O=C(C(N12)=C(COC(N)=O)CS[C@]2([H])[C@@](NC(CC3=CC=CS3)=O)(OC)C1=O)O
Biological Activity: Cefoxitin is a cephalosporin-class antibiotic. Cefoxitin is highly stable against β-Lactamase (HY-P2998). Cefoxitin has a broad spectrum of antibacterial activity, including Gram-negative and Gram-positive bacteria[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cefoxitin | 99.92% | Cefoxitin is a cephalosporin-class antibiotic. Cefoxitin is highly stable against β-Lactamase (HY-P2998). Cefoxitin has a broad spectrum of antibacterial activity, including Gram-negative and Gram-positive bacteria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cefoxitin (Standard) | ≥98% | Cefoxitin (Standard) is the analytical standard of Cefoxitin. This product is intended for research and analytical applications. Cefoxitin is a cephalosporin-class antibiotic. Cefoxitin is highly stable against β-Lactamase (HY-P2998). Cefoxitin has a broad spectrum of antibacterial activity, including Gram-negative and Gram-positive bacteria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. E O Stapley, et al. Cefoxitin and cephamycins: microbiological studies. Rev Infect Dis. Jan-Feb 1979;1(1):73-89. [Content Brief]
- [2]. R N Brogden, et al. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979 Jan;17(1):1-37. [Content Brief]
- [3]. Venkata Raveendra Pothineni, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018; 12: 2915–2921. [Content Brief]
Keywords
